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ABSTRACT 
This paper is an opinion in the form of a letter to the editor. Here the authors 
highlight the issue of pharmaceutical price asymmetry in some countries. The letter 
explains the need for a comprehensive policy framework in the pricing of 
pharmaceutical drugs. 
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1. OPINION 
Asymmetrical information is commonly observed in market economies and is generally 
considered as a cause for concern as it might lead to adverse selection and moral hazard [1]. 
In certain countries like India, Philippines and Iran, price control is imposed on essential 
drugs. However, in other countries such as Malaysia, Korea and New Zealand, a free market 
system is practiced. In countries with a free market system apprehensions on the availability 
and affordability of medicines do exist. Manufacturers, distributors and retailers are given 
freedom to set the price in such countries leading to considerable price variations [2] and high 
markups [3] in medicines.  
Though such price variations are common across the world, consumers in certain 
countries like Malaysia differ from the US and German consumers who prefer generic 
medicines due to price advantages. This situation leads to potential exploitation of the 
consumers in countries where there is no price control. In contrast, India and Australia require 
the pharmaceutical companies to register the recommended retail price in a database [4]. As 
this approach ensures that the consumers have better access to essential drugs some [5] even 
argue that that exceptions should be made for the medical field though certain governments 
prefer a free market system. 
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In the economies where price control is not enforced the governments should at least take 
measures to improve the transparency in pharmaceutical pricing. However, transparency 
alone may not improve the situation in free market economies and hence the governments 
should take cognizance of the WHO recommendations on regulation of markups in 
pharmaceutical supply and distribution. It is recommended that the cost of medicines should 
be taken into consideration while computing the profit markups and fixed percentage markups 
should be avoided to prevent price escalation. Overall, consumers would benefit from better 
availability and affordability of medicines if transparency and regulatory controls are ensured 
in pharmaceutical pricing.  
ACKNOWLEDGEMENT 
The authors thank Universiti Malaysia Pahang for the research grant RDU170307. 
REFERENCES 
[1] D. C. Ling, E R Berndt & M. K. Kyle. Deregulating direct-to-consumer marketing of 
prescription drugs: effects on prescription and over-the-counter product sales. The Journal 
of Law and Economics. 45(S2), 2002, pp. 691-723. 
[2] M. A. Hassali, C. S. Tan, Z. Y. Wong, F. Saleem, & A. A. Alrasheedy. Pharmaceutical 
pricing in Malaysia. In Pharmaceutical Prices in the 21st Century pp. 171-188. Adis, 
Cham; 2015 
[3] T. C. Siang, M. A. Hassali, A. A. Alrasheedy, & F. Saleem.  Perceptions of general 
practitioners towards pharmaceutical price war and assessment medicines price variation 
among general practitioners’ clinics in the state of Penang, Malaysia. Journal of Medical 
Marketing. 14(2-3), 2014, pp.125-132. 
[4] Y. Meikeng, M. Carvalho, F. Zainal. Making it cheaper for patients, The Star Online, 
https://www.thestar.com.my/news/nation/2017/06/18/making-it-cheaper-for-patients-
ministry-wants-pharmaceutical-firms-to-display-prices-on-medicines/  2017 
[5] S. Rachagan, A. H. Syed & S. Sothirachagan. Examining the interface between the 
objectives of competition policy and intellectual property, Intergovernmental Group of 
Experts on Competition Law and Policy, Fifteenth Session, Geneva; 2016.   
